TMCnet News
argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026July 16, 2026 A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Participants can access the conference call by dialing 800-590-8290 (United States and Canada) or 240-690-8800 (International). Country specific dial-in numbers are listed below: Belgium 32 2290 4635 Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call. About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Parnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube. Contacts Media: Ben Petok Investors: Alexandra Roy 
|
